Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Egetis Therapeutics

8.06 SEK+0.88 %9/9 17:29
Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+0.88 %
+13.84 %
+45.75 %
+56.20 %
+50.94 %
+50.94 %
+104.05 %
+27.31 %
-41.75 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
3.96B SEK
Turnover
6.48M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
6/11
2026

Interim report Q3'26

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-09-04 08:00

Presentationer om Emcitate® (tiratrikol) vid ETA:s och ESPE:s kongresser i september 2026

Egetis Therapeutics
Press release2026-09-04 08:00

Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026

Egetis Therapeutics
Press release2026-09-03 08:10

Egetis Therapeutics deltar i kommande investerarkonferenser i september

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-09-03 08:10

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

Egetis Therapeutics
Press release2026-08-31 08:00

Tiratricol beviljas särläkemedelsstatus för MCT8-brist i Japan

Egetis Therapeutics
Press release2026-08-31 08:00

Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q2'26
Webcast2026-08-21 14:00

Egetis Therapeutics, Audiocast, Q2'26

Egetis Therapeutics
Regulatory press release2026-08-21 07:00

Egetis Kvartalsrapport Q2 2026

Egetis Therapeutics
Regulatory press release2026-08-21 07:00

Egetis' Interim report Q2 2026

Egetis Therapeutics
Press release2026-08-07 13:30

Inbjudan till presentation av Egetis kvartalsrapport Q2 2026 den 21 augusti 2026

Egetis Therapeutics
Press release2026-08-07 13:30

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

Egetis Therapeutics
Press release2026-06-10 15:00

Egetis meddelar att Behind the Mystery-avsnittet om MCT8-brist sänds i repris på Lifetime-kanalen i USA

Egetis Therapeutics
Press release2026-06-10 15:00

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Egetis Therapeutics
Regulatory press release2026-05-29 10:00

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Regulatory press release2026-05-29 10:00

Ändring av antalet aktier och röster i Egetis Therapeutics

Egetis Therapeutics
Press release2026-05-19 14:00

Egetis presenterar drivkrafter för vårdresursanvändning och kostnader vid MCT8‑brist på ISPOR 2026

Egetis Therapeutics
Press release2026-05-19 14:00

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics
Press release2026-05-13 16:45

Utnyttjande av optioner i personaloptionsprogram och meddelande om insynshandel

Egetis Therapeutics
Press release2026-05-13 16:45

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics
Press release2026-05-07 10:00

Egetis Therapeutics deltar vid ledande medicinska konferenser under 2026

Egetis Therapeutics